Home  |  Contact

Cellosaurus XG-1 (CVCL_4797)

[Text version]

Cell line name XG-1
Synonyms XG1; XG 1
Accession CVCL_4797
Resource Identification Initiative To cite this cell line use: XG-1 (RRID:CVCL_4797)
Comments Characteristics: IL6 dependent.
Characteristics: Produces IgA kappa.
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Transcriptome analysis.
Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
Derived from sampling site: Peripheral blood.
Sequence variations NRAS p.Gly12Arg (c.34G>C) (PubMed=21173094).
TP53 p.Tyr126Asn (c.376T>A) (ClinVar=VCV000428871) (PubMed=21173094).
HLA typing Source: Direct_author_submission
Class I
HLA-AA*02:01,29
HLA-BB*40,44
HLA-CC*02:02,16:01
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
Web pages https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
http://www.cells-talk.com/index.php/page/copelibrary?key=XG-1
Publications

PubMed=1753108
Jourdan M., Zhang X.-G., Portier M., Boiron J.-M., Bataille R., Klein B.
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
J. Immunol. 147:4402-4407(1991)

PubMed=7504521; DOI=10.1002/gcc.2870080204
Raynaud S.D., Bekri S., Leroux D., Grosgeorge J., Klein B., Bastard C., Gaudray P., Simon M.-P.
Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies.
Genes Chromosomes Cancer 8:80-87(1993)

PubMed=8204890; DOI=10.1182/blood.V83.12.3654.3654
Zhang X.-G., Gaillard J.-P., Robillard N., Lu Z.-Y., Gu Z.-J., Jourdan M., Boiron J.-M., Bataille R., Klein B.
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.
Blood 83:3654-3663(1994)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5
Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H., Bast B.J.E.G.
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer Genet. Cytogenet. 109:99-107(1999)

PubMed=10557056; DOI=10.1038/sj.leu.2401563
Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.
Detection of MUM1/IRF4-IgH fusion in multiple myeloma.
Leukemia 13:1812-1816(1999)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=16956823
Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T., Ahmann G., Mancini C., Brents L.A., Kumar S., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M., Valdez R., Trent J.M., Stewart A.K., Carpten J., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=21173094; DOI=10.3324/haematol.2010.033456
Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=30545397; DOI=10.1186/s13045-018-0679-0
Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S., Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M., Pellat-Deceunynck C.
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
J. Hematol. Oncol. 11:137-137(2018)

Cross-references
Gene expression databases ArrayExpress; E-TABM-937
Other Wikidata; Q54994677
Polymorphism and mutation databases Cosmic; 742957
Cosmic; 2081411
Cosmic; 2367276
IARC_TP53; 28500
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number17